AARON CLOUTIER: Open Payments
NPI 1013448067 · NEW HAVEN, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$436 in 22 payments from 13 companies in 2025. Trend: 2023 $243 · 2024 $501 · 2025 $436
Food & beverage: $436
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $103 |
| ABBVIE INC. | 3 | $64 |
| Novo Nordisk Inc | 3 | $54 |
| Abbott Laboratories | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Boston Scientific Corporation | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
Products named: CAPLYTA, QULIPTA, FREESTYLE LIBRE 3, Wegovy, Veozah, VOQUEZNA, WaveWriter Alpha Prime 16, TRELEGY ELLIPTA.
Industry payments across MI — which companies pay providers there.
